ArticleEuropean journal of pediatrics2010
Treatment of symptomatic congenital cytomegalovirus infection with intravenous ganciclovir followed by long-term oral valganciclovir.
Article in European journal of pediatrics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial
The Leiden CONCERT Study 2.0 Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Non-Randomized Trial With Historical Control Group
Who cites it
25 citing papers in PubMed, 123 citations in OpenAlex.
- Foscarnet Versus Ganciclovir for Severe Congenital Cytomegalovirus Infection: Short- and Long-Term Follow-Up.Viruses · 2025Trial
- Valganciclovir for symptomatic congenital cytomegalovirus disease.The New England journal of medicine · 2015Trial
- Changes in Neutrophil Count During Valganciclovir Therapy for Symptomatic Congenital Cytomegalovirus Infection.Biomedicines · 2025Article
- Congenital CMV infection and central nervous system involvement: mechanisms, treatment, and long-term outcomes.European journal of pediatrics · 2025Review
- Progress and Challenges in the Management of Congenital Cytomegalovirus Infection.Clinics and practice · 2024Review
- Congenital Cytomegalovirus Severity Definitions and Treatment Decisions around the World: A Systematic Scoping Review of the Literature.Journal of clinical medicine · 2024Article
- Treatment of congenital cytomegalovirus infection.Clinical and experimental pediatrics · 2023Article
- Role of Valganciclovir in Children with Congenital CMV Infection: A Review of the Literature.Children (Basel, Switzerland) · 2023Review
- Progressive, Long-Term Hearing Loss in Congenital CMV Disease After Ganciclovir Therapy.Journal of the Pediatric Infectious Diseases Society · 2022Article
- Cytomegalovirus and Epstein-Barr Virus Associations with Neurological Diseases and the Need for Vaccine Development.Vaccines · 2020Review
- Long-Term Clinical, Audiological, Visual, Neurocognitive and Behavioral Outcome in Children With Symptomatic and Asymptomatic Congenital Cytomegalovirus Infection Treated With Valganciclovir.Frontiers in medicine · 2020Article
- Results of a Targeted Screening Program for Congenital Cytomegalovirus Infection in Infants Who Fail Newborn Hearing Screening.Journal of the Pediatric Infectious Diseases Society · 2019Article
- Efficacy of Valganciclovir Treatment Depends on the Severity of Hearing Dysfunction in Symptomatic Infants with Congenital Cytomegalovirus Infection.International journal of molecular sciences · 2019Article
- Long-term hearing outcomes of children with symptomatic congenital CMV treated with valganciclovir.International journal of pediatric otorhinolaryngology · 2019Article
- [A review on the prevention and treatment of congenital cytomegalovirus infection in mothers and infants].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2018Review
- Potential Benefit of Selective CMV Testing after Failed Newborn Hearing Screening.International journal of neonatal screening · 2018Review
- Primary Human Cytomegalovirus (HCMV) Infection in Pregnancy.Deutsches Arzteblatt international · 2017Review
- Symptomatic Congenital Cytomegalovirus Infection in Children of Seropositive Women.Frontiers in pediatrics · 2017Article
- Awareness of Cytomegalovirus Infection among Pregnant Women in Geneva, Switzerland: A Cross-sectional Study.International journal of environmental research and public health · 2015Article
- Safety of alternative antiviral agents for neonatal herpes simplex virus encephalitis and disseminated infection.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2014Review
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Congenital cytomegalovirus infection is the most common cause of nonhereditary sensorineural hearing loss and an important cause of psychomotor retardation. Earlier studies showed that 6-weeks' treatment with ganciclovir, starting in the neonatal period, prevented hearing deterioration at 6 months, but in one-fifth of the infants, the effect was not sustained at age 12 months. The aim of this preliminary retrospective study was to investigate the effectiveness and safety of long-term treatment with ganciclovir/valganciclovir for congenital cytomegalovirus infection. Twenty-three infants with culture-proven symptomatic congenital cytomegalovirus infection were treated with ganciclovir for 6 weeks followed by oral valganciclovir to age 12 months. Audiometry was performed at least three times in the first year, in addition to physical examination including neurological and developmental assessment. At age >or=1 year, hearing was normal in 76% of affected ears compared to baseline (54%). In 25 normal ears at birth no deterioration was found at >or=1 year. These results were significantly better than reported in a historical control group of similar infants treated for 6 weeks only (P= 0.001). Viral load monitoring demonstrated sustained virological response. Four of the children (18%) had mental retardation. The main side effect of treatment was transient neutropenia. In conclusion, prolonged therapy of symptomatic congenital CMV infection with intravenous ganciclovir followed by oral valganciclovir is safe, and it appears to lead to a better auditory outcome than short-term treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.